FN2 Earnings Intelligence

Guardant Health, Inc. earnings overview

Latest Guardant Health, Inc. (GH) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

GH FY2026 Q3 · Calendar Q4 2026

Guardant Health, Inc.

The supplied Q3 analysis supports a growth case built on expansion across oncology, screening and biopharma/data, with Shield growth and broader payer coverage as important contributors. The raised outlook and cost-reduction work are constructive, but the thesis depends on sustained demand, reimbursement progress and successful regulatory execution.

EPS surprise+61.3%
Market move-9.0%

Get the GH recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.